- * Males or non-pregnant females aged ≥ 18 years at the time of vaccination.
- * Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the On-study period. Females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine.
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
NCT02214225 | PHASE 3 | INTERVENTIONAL
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Site
Huntsville,Alabama,United States,35802
Site
Los Angeles,California,United States,90036
Site
San Diego,California,United States,92108
Site
Milford,Connecticut,United States,06460
Site
Jacksonville,Florida,United States,32207
Site
Melbourne,Florida,United States,32935
Site
Savannah,Georgia,United States,31406
Site
Meridian,Idaho,United States,83642
Site
Peoria,Illinois,United States,61614
Site
Mishawaka,Indiana,United States,46545
Site
Witchita,Kansas,United States,67207
Site
Rockville,Maryland,United States,20850
Site
Methuen,Massachusetts,United States,01844
Site
Saint Louis,Missouri,United States,63141
Site
Bellevue,Nebraska,United States,68005
Site
Las Vegas,Nevada,United States,89104
Site
Binghamton,New York,United States,13901
Site
Rochester,New York,United States,14642
Site
Charlotte,North Carolina,United States,28209
Site
Raleigh,North Carolina,United States,27609
Site
Wilmington,North Carolina,United States,28401
Site
Winston-Salem,North Carolina,United States,27103
Site
Oklahoma City,Oklahoma,United States,73112
Site
Mount Pleasant,South Carolina,United States,29464
Site
Bristol,Tennessee,United States,37620
Site
Jefferson City,Tennessee,United States,37760
Site
Knoxville,Tennessee,United States,37912
Site
Knoxville,Tennessee,United States,37938
Site
Austin,Texas,United States,78705
Site
Forth Worth,Texas,United States,76135
Site
San Angelo,Texas,United States,76904
Site
Salt Lake City,Utah,United States,84124
Site
Charlottesville,Virginia,United States,22911
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov